Un medicament împotriva cancerului pancreatic obține aprobarea Administrației pentru Alimente și Medicamente din Statele Unite

The FDA has approved Rasonque, a new pancreatic cancer drug from Revolution Medicines, which has shown to double survival rates in advanced cases. This once-daily pill targets RAS proteins that promote tumor growth. Priced at $39,800 for a 30-day supply, it is available for patients who have previously received treatment or cannot undergo chemotherapy. Early access programs have already provided relief to some patients. Analysts predict significant revenue growth for the drug, estimating annual sales could reach $11.5 billion, given the high demand and unmet medical needs.